Ankylosing in Medical News

Driven by Sales of Enbrel, Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in 2008

... immune diseases known as the seronegative SpAs - ankylosing spondylitis, psoriatic arthritis, and reactive ... for the treatment of psoriatic arthritis and ankylosing spondylitis. "Simponi's advantages over ... diseases. While the combined market in 2008 for ankylosing spondylitis and psoriatic arthritis was ...

SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

... arthritis, active psoriatic arthritis and active ankylosing spondylitis. SIMPONI is the first ... Rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis are chronic inflammatory diseases ... rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis who had previously received a wide ...

MEDVERSATION(TM) Website Launched by Centocor to Facilitate Physician-Patient Dialogue About Drug Benefits and Risks

... Crohn's disease (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis ... for rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, or plaque ... Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative ...

LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis

... 1999. The drug treats psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid ... arthritis, Crohn's disease, psoriasis, ankylosing spondylitis and juvenile idiopathic arthritis -- ... idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis and plaque psoriasis. In addition to ...

Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

... rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Golimumab, Centocor's ... and the Golimumab - A Randomized Study in ankylosing Spondylitis Subjects of a Novel Anti-TNF mAB ... in the peak of their productive years. About ankylosing Spondylitis ...

Increased cancer risk following the use of radioactive Radium-224 in the therapy

... ankylosing Spondylitis (Bechterew's Disease) is a painful ... conducted a long-term follow-up study of 1,471 ankylosing spondylitis patients, whose disease symptoms were ... of 224Radium. A control cohort of 1,324 ankylosing spondylitis patients treated without the use of ...

Data Show that Abbott's HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years

... annual meeting in Paris. "There is no cure for ankylosing spondylitis and the goal of therapy is to relieve ... that adalimumab can be an effective treatment for ankylosing spondylitis." Three-Year ATLAS Data Summary ... was one death caused by malignancy. About ankylosing Spondylitis (AS) AS is a rheumatic condition ...

Adalimumab therapy effective in AS, RA and PsA patients refractory to other anti-TNF therapies

... therapy is effective and well-tolerated in ankylosing spondylitis (AS), rheumatoid arthritis (RA) and ... found to have a mean reduction in BASDAI (Bath ankylosing Spondylitis Disease Activity Index) of -2.4 ... other treatment options for their diseases." ankylosing spondylitis 61% of AS patients who had lost ...

Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab)

... in Up to 40 Percent of People with ankylosing Spondylitis (Spinal Arthritis) ABBOTT PARK, ... half compared to patients treated with placebo. ankylosing spondylitis is an inflammatory disease of the ... witH Adalimumab in Patients with active ankylosing SpOnDYlitis) trial was designed to examine the ...

Abbott's HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care

... severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and moderate to severe ... therapy. In HUMIRA clinical trials for ankylosing spondylitis, psoriatic arthritis and Crohn's ... signs and symptoms in patients with active ankylosing spondylitis. Earlier this year, HUMIRA was ...

IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS

... of receiving infliximab (IFX) anti-TNF therapy, 61.8% of patients with ankylosing spondylitis (AS) showed substantial clinical benefit (ASAS40, ASsessment ... the United Kingdom) recruited to the 96-week open-label EASIC (European ankylosing Spondylitis Infliximab Cohort) trial had previously participated in the ...

Schering-Plough Reports Financial Results for 2009 First Quarter

... other Asian markets) for rheumatoid arthritis, early rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn's disease, ... subcutaneous therapy for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, marking the first approval in the world for this innovative ...

Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis

... is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis. -- ENBREL is indicated for the treatment of adult patients ... disease, such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, or psoriasis, have too much TNF in their ...

Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis

... for HUMIRA and 4 percent for placebo. In HUMIRA clinical trials for ankylosing spondylitis, psoriatic arthritis, Crohn's disease and plaque psoriasis, ... is also indicated for reducing signs and symptoms in patients with active ankylosing spondylitis. HUMIRA is indicated for reducing the signs and symptoms and ...

New findings show Enbrel significantly reduced levels of C-reactive protein

... is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis. ENBREL is indicated for the treatment of adult patients ... called TNF. People with an immune disease, such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis, have too much TNF in ...

Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab

... trials for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis and is being investigated for administration by either monthly ... innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's ...

UT rheumatologists discover 2 genes related to disabling form of arthritis

... Medical School at Houston has led to the discovery of two genes that cause ankylosing spondylitis, an inflammatory and potentially disabling disease. The ... brings the scientific community two steps closer to fully understanding ankylosing spondylitis or AS, a chronic form of arthritis that attacks the spine and ...

Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers

... in patients who do not respond adequately to methotrexate alone. ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis. ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who ...

Study aims to induce recovery from ankylosing spondylitis

... Chinese patients will soon have the opportunity to take part in a study of a novel therapy aimed at reversing the autoimmune disease, ankylosing spondylitis. Approximately 200 patients will be chosen to participate in a clinical trial that aims to merge the latest molecular discoveries ...

Diagnosis of arthritis 5 years earlier in childless women compared to those with children

... Denmark, Thursday 11 June 2009: Nulliparous women (those who have not given birth to children) are diagnosed with chronic arthritides (including ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis (RA) an average of 5.2 years before parous women (those who have given birth to children), ...

Johnson & Johnson Highlights Pharmaceutical Growth Strategies and Robust Pipeline to Address Unmet Medical Needs

... suffer from diseases of the immune system, and there are approximately 10 million people living with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and plaque psoriasis. Infectious Diseases -- The company is ...

Chlamydia may play role in a type of arthritis

... group of arthritidies that share clinical features such as inflammatory back pain and inflammation at sites where tendons attach to bone. It includes ankylosing spondylitis (AS), psoriatic arthritis, inflammatory bowel-disease-related arthritis, reactive arthritis (ReA) and undifferentiated spondylarthritides ...

New Report by BioTrends Research Group to Highlight the Launch of SIMPONI(R) (golimumab)

... therapy, SIMPONI is approved for the treatment of moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and active ankylosing spondylitis. The product will be available in two dosing delivery forms: the SIMPONI SmartJect autoinjector and a prefilled syringe. ...

Medarex to Receive Milestone Payment for Approval of SIMPONI(TM) for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

... also known as CNTO 148) as a once-monthly subcutaneous treatment for adults with active forms of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. SIMPONI is a new, human anti-tumor necrosis factor (TNF) monoclonal antibody that was generated by Medarex's UltiMAb(R) technology ...

Rheumatoid Arthritis Therapeutics in Taiwan

... of life. (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) Frost & Sullivan, Research Analyst Sushma Rajan says, "Besides ankylosing spondylitis (AS) and system lupus erythmatosus (SLE), rheumatoid arthritis (RA) is one of the most common rheumatic diseases in Taiwan, with an ...

Medarex Announces 2008 Fourth Quarter and Year End Financial Results

... approval in Europe for golimumab (CNTO 148), a human anti-TNF-alpha antibody for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. A regulatory filing for market approval in the U.S. has also been submitted. Announcing the receipt of other milestone payments ...

Medarex to Receive Milestone Payment for Approval of STELARA(TM) (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis

... marketing approval as a once-monthly subcutaneous anti-TNF-alpha human antibody in the U.S. and in Europe for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, and in Phase 2 for the treatment of ulcerative colitis; and CNTO 95, an anti-integrin human antibody in Phase 2 ...

FDA Demands Tougher Warnings on Immunosuppressive Drugs

... and are approved to treat several conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis and Crohn's disease. All four drugs already carry black-box warnings related to different safety issues, including fungal infections. ...

CV risk management should be mandatory in RA and other types of inflammatory rheumatic disease

... Paris, France, Friday 13 June 2008: Rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients should undergo compulsory cardiovascular (CV) risk management and existing CV risk ...

New Long-Term HUMIRA(R) (adalimumab) Data Show Up to Seven-Year Efficacy with Combination Treatment for Rheumatoid Arthritis

... is the only fully human monoclonal antibody approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), plaque psoriasis, ankylosing spondylitis (AS) and Crohn's disease in the United States and Europe. HUMIRA resembles antibodies normally found in the body. It works by blocking ...

HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity

... is the only fully human monoclonal antibody approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), plaque psoriasis, ankylosing spondylitis (AS) and Crohn's disease in the United States and Europe. HUMIRA resembles antibodies normally found in the body. It works by blocking ...

Researchers who helped millions with arthritis receive prestigious Janssen Award

... led to the development of new drugs which tackle the inflammation and tissue destruction caused by rheumatoid arthritis and other diseases including ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohns disease and ulcerative colitis. The treatments they developed, now used by millions of people ...

Marc Feldmann and Sir Ravinder Maini win Dr. Paul Janssen Award for Biomedical Research

... effective target for treatment not only in rheumatoid arthritis but also other chronic inflammatory conditions, such as inflammatory bowel disease, ankylosing spondylitis and psoriasis. This discovery suggested that other cytokine messenger molecules are also good treatment targets and has led to an ...

Medarex Announces 2008 First Quarter Financial Results

... marketing approval of golimumab (CNTO 148), a human anti-TNF antibody for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, that was generated using Medarex's UltiMAb(R) technology; -- Announcing the receipt of a milestone payment from our licensing ...

Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis

... HUMIRA can be used alone or in combination with MTX or other DMARDs. HUMIRA is indicted for reducing signs and symptoms in patients with active ankylosing spondylitis. HUMIRA is indicated for reducing the signs and symptoms and inducing and maintaining clinical remission in adults with moderately to ...

Video: New Autoimmunity Public Service Campaign Alerts Men About Their Autoimmune Disease Risk

... in men tend to be more severe. There are a few autoimmune diseases that men are just as or more likely to develop as women, including: -- ankylosing spondylitis -- Type 1 diabetes -- Wegener's granulomatosis -- Psoriasis In addition, diseases that affect blood vessels can lead to ...

Arthritis sufferers fund arthritis research

... Dr Gethin Thomas will be the inaugural recipient of the $300,000 three-year fellowship, which will fund his research investigating the causes of ankylosing spondylitis (AS). This is a form of arthritis affecting the spine resulting in joint fusion and immobility, and osteoporosis, a disease ...

Schering-Plough Reports Financial Results for Third Quarter of 2007

... in countries outside the United States (except in Japan and certain other Asian markets) for rheumatoid arthritis, early rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn's disease, pediatric Crohn's disease and ulcerative colitis. Global sales of NASONEX, an ...

Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months

... is a breakthrough product approved for the treatment of chronic inflammatory diseases, including rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis. Enbrel is now ranked sixth among the top pharmaceutical products ranked globally by sales and is the ...